These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22607366)

  • 1. Rare or orphan diseases -- a useful political concept.
    Baxter P
    Dev Med Child Neurol; 2012 Jul; 54(7):579. PubMed ID: 22607366
    [No Abstract]   [Full Text] [Related]  

  • 2. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ
    Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
    [No Abstract]   [Full Text] [Related]  

  • 3. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
    Engstrom LO
    Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
    [No Abstract]   [Full Text] [Related]  

  • 5. NIH gives money for orphan development.
    Watanabe ME
    Nat Med; 2000 Nov; 6(11):1197-8. PubMed ID: 11062512
    [No Abstract]   [Full Text] [Related]  

  • 6. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomedical research. A low-stress scheme for overhauling NIH's structure.
    Kaiser J
    Science; 2003 Aug; 301(5633):574-5. PubMed ID: 12893911
    [No Abstract]   [Full Text] [Related]  

  • 8. Adopting an orphan.
    Rinaldi A
    EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 10. A word to the wise.
    Palca J
    Hastings Cent Rep; 1994; 24(2):5. PubMed ID: 8026940
    [No Abstract]   [Full Text] [Related]  

  • 11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH stem-cell guidelines face stormy ride.
    Wadman M
    Nature; 1999 Apr; 398(6728):551. PubMed ID: 10217131
    [No Abstract]   [Full Text] [Related]  

  • 14. The pedagogical significance of the Bush stem cell policy: a window into bioethical regulation in the United States.
    Snead OC
    Yale J Health Policy Law Ethics; 2005; 5(1):491-504. PubMed ID: 15742591
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of voluntary disease organizations in research and development of orphan drugs.
    Horansky R
    Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293
    [No Abstract]   [Full Text] [Related]  

  • 16. Task force set up to combat threat of political interference.
    Check E
    Nature; 2003 Nov; 426(6964):218. PubMed ID: 14628013
    [No Abstract]   [Full Text] [Related]  

  • 17. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 18. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Commission on Digestive Diseases.
    Hoofnagle JH
    Hepatology; 2006 Jul; 44(1):6. PubMed ID: 16799964
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
    Grienenberger A
    J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.